{
    "nctId": "NCT02692755",
    "briefTitle": "Palbociclib / Letrozole or Fulvestrant in African American Women With HR+ HER2- Breast Cancer",
    "officialTitle": "Phase II Safety Study of Palbociclib in Combination With Letrozole or Fulvestrant in African American Women With Hormone Receptor Positive HER2 Negative Advanced Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Hormone Receptor Positive HER-2 Negative Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2, PHASE3",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 35,
    "primaryOutcomeMeasure": "Number of Patients Who Complete Planned Oncologic Therapy Without the Development of a Hematological Event",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Self-identified Black, African or African American women of \u2265 18 years of age with proven diagnosis of advanced adenocarcinoma of the breast (locoregionally recurrent or metastatic disease)\n2. ER-positive and/or PgR-positive tumor based on local laboratory results\n3. HER2-negative breast cancer based on local laboratory results (test to be used as per local practice)\n4. Patients must be appropriate candidates for letrozole or fulvestrant therapy\n5. Eastern Cooperative Oncology Group (ECOG) performance status 0-2\n6. Adequate bone marrow function:\n\n   * Absolute Neutrophil Count (ANC) \u2265 1,000/mm3 (1.0 x 109/L);\n   * Platelets \u2265100,000/mm3 (100 x 109/L);\n   * Hemoglobin \u22659 g/dL (90 g/L).\n\nExclusion Criteria:\n\n1. Current use of food or drugs known to be potent inhibitors or inducers of CYP3A4\n2. Active uncontrolled or symptomatic brain metastases. Previously treated and clinically stable, as per Investigator's judgment, brain metastases are permitted.\n3. Previous CDK4/6 inhibitor\n\n   -",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}